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ABSTRACT 
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF THE 
ZEBRAFISH GENE QUETSCHKOMMODE (que) 
SEPTEMBER 2012 
TIMO FRIEDRICH, B.S., UNIVERSITÄT KONSTANZ, KONSTANZ 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Gerald B. Downes 
 
 Locomotion in vertebrates depends on proper formation and maintenance of 
neuronal networks in the hind-brain and spinal cord. Malformation or loss of factors 
required for proper maintenance of these networks can lead to severe neurodegenerative 
diseases limiting or preventing locomotion. A powerful tool to investigate the genetic and 
cellular requirements for development and/or maintenance of these networks is a 
collection of zebrafish mutants with defects in motility. The zebrafish mutant 
quetschkommode (que) harbors a previously unknown gene defect leading to abnormal 
locomotor behavior.  Here I show that the que mutants display a seizure-like behavior 
starting around four days post fertilization (dpf) that is characterized by a lack of an 
initial high amplitude body bend (C-bend) and simultaneous contra-lateral contractions 
leading to a seizure-like phenotype and paralysis. Peripheral nerve recordings show a 
significant increase in the number of initiated swimming bouts and overlap between left 
and right motor neuron activity. These data suggest that the que mutation leads to defects 
vi 
 
in nervous system function, at the level of motor neurons or central control of motor 
neurons. I have genetically mapped the que locus to a 0.36cM interval on chromosome 22 
using meiotic mapping. I identified a splice mutation in the gene ‘dihydrolipoamide 
branched-chain transacylase E2’ (dbt) as defective in que. An orthologous mutation in 
humans leads to Maple Syrup Urine Disease (MSUD), a devastating metabolic disorder 
leading to seizures, mental retardation, coma and neonatal death if untreated. In zebrafish, 
dbt is expressed throughout early development and dbt transcripts become enriched in the 
hind-brain as well as in the gut and liver by 96 hpf. In MSUD patients levels of branched 
chain amino acids (BCAA) and their keto acids are significantly increased due to the 
essential role of the DBT enzyme for the BCAA metabolic pathway. The que mutation 
causes a significant increase of branched chain amino acids in the zebrafish mutant and a 
strong decrease of neurotransmitters such as glutamate and GABA as well as precursors 
like glutamine. I hypothesize that reduced neurotransmitter levels in que mutants lead to 
the observed motility phenotype. Consistent with this hypothesis, I show a tissue specific 
reduction of glutamate in the hind-brain and spinal cord of que mutants. To evaluate the 
que mutant’s potential as a vertebrate model for MSUD I performed a pilot drug screen 
using a selection of metabolites of the pathway as well as diet additives currently 
evaluated in clinical trials. Conversely, application of phenylbutyrate, one of the diet 
additives, increased the swimming performance of que mutant embryos, while the keto 
acid α-ketoisocaproate (KIC), one of the elevated keto acids in human patients, decreased 
the percentage of larvae capable of swimming. These results help establish the zebrafish 
que mutant as a new model for MSUD disease that can be used to further the 
understanding of this disorder and to help identify therapeutic agents. 
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CHAPTER 1 
BACKGROUND AND INTRODUCTION 
 
1.1 Introduction 
 Locomotion in vertebrates depends on proper formation and maintenance of 
neuronal networks in the hindbrain and spinal cord. Malformation or loss of factors 
required for the function of these networks can lead to severe neurodegenerative diseases 
limiting or preventing locomotion. The zebrafish mutant quetschkommode (que) 
demonstrates abnormal seizure-like motor behavior (Granato et al. 1996). Previous to this 
work, the mutation underlying the que phenotype had not been determined nor had its 
behavior been characterized in detail. Wild-type larvae respond to touch stimuli to the 
head at 4 days post fertilization (dpf) with a high amplitude body bend with the tip of the 
tail touching the head (C-Bend) followed by alternating body bends propelling the larvae 
away from the direction of the stimulus. While being indistinguishable from wild-type 
siblings until after 3 dpf que mutants mostly fail to perform C-bends, compress 
rostrocaudally and remain in this seizure-like state until the end of the response with only 
minimal, mostly uncoordinated tail movements. In this dissertation I have compared the 
tail angle of que mutants to known muscle and central nervous system (CNS) defect 
mutants and use peripheral nerve recordings to determine whether que mutants harbor a 
neurological or muscle defect as described in Chapter 2. In Chapter 3, the mutation was 
determined and found that the mutated gene has implications for Maple Syrup Urine 
Disease (MSUD), a human metabolic disorder. I characterized the metabolic criteria such 
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as severe changes in free amino acid and neurotransmitter levels (Chapter 4). Part of this 
characterization was also a pilot drug screen with the intention of testing a working 
model of how the que gene leads to the observed locomotor defect as well as testing the 
feasibility of using the que mutant as a tool to screen small compound libraries for new 
potential drugs to treat MSUD.  
1.2 Zebrafish as a model system 
 Zebrafish as a model system to study vertebrate development has many key 
advantages and benefits. First, during the initial five days post fertilization the neuronal 
networks responsible for locomotion go through several stages of development 
characterized by increasing complexity. During this transition the embryos and larvae 
display various discrete motor phenotypes during early development such as spontaneous 
movement after 17hpf, touch evoked tail coiling after 21hpf and escape responses after 
27hpf (Granato et al. 1996; McKeown et al. 2012). These defined behaviors can be used 
to find new genes required for neuronal network formation by mapping chemically 
induced mutations in mutants displaying motility defects (Granato et al. 1996; Haffter et 
al. 1996; Downes and Granato 2004; Gleason et al. 2004; Hirata et al. 2005; Olson, 
Sgourdou, and Downes 2010; McKeown et al. 2012). Second, maintenance of many 
different transgenic lines is relatively inexpensive. Third, embryos develop externally and 
most organ systems are formed at 5 dpf. This rapid development as well as the initial 
transparency of the embryo makes zebrafish highly amenable to optical methods. Forth, a 
great variety of genetic tools and resources are shared among the research community. 
Among these resources are mutant collections obtained from insertional mutagenesis 
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(Amsterdam et al. 1999) or  N-ethyl-N-nitrosourea (ENU) mutagenesis screens (Granato 
et al. 1996).  
 Zebrafish mutants have been used for forward genetics to search for genes 
involved in many aspects of development such as cardiac muscle formation 
(Langenbacher et al. 2011) and eye development (Tschopp et al. 2010) but also for 
seeking novel genes involved in seizure resistance (Baraban et al. 2007) and in neuronal 
network formation (Wolman and Granato 2012). Mapping of these mutants is facilitated 
by a sequenced zebrafish genome and extensive polymorphism databases available 
online. Fifth, knockdown strategies using antisense morpholino oligomers, which are 
injected at the 1-4 cell stage, can be used to knock down translation of specific transcripts 
of interest (Bill et al. 2009; McKeown et al. 2012). Lastly, the aquatic habitat facilitates 
pharmacological approaches and screens; most water soluble compounds can simply be 
applied to the external embryo medium (Parng et al. 2002; Hao et al. 2010; Zhong and 
Lin 2011). Taken together, these benefits make zebrafish an excellent model to study 
genes and factors involved in the development of locomotion. 
1.3 Motility mutants as a tool to study neuronal network function 
  In a large scale mutagenesis screen zebrafish were exposed to the mutagen ENU. 
After outcrossing multiple mutations the offspring were analyzed for developmental and 
behavioral defects. This experiment yielded a large collection of mutants with various 
phenotypes of abnormal locomotion (Granato et al. 1996). The 166 obtained mutants, that 
together contain around 48 genes, fall into 14 phenotypic groups. The 8 mutants of the 
accordion group respond to touch at 24 hpf with rostrocaudal compression and were 
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therefore grouped together due to the similarity to the musical instrument (Table 1.1). 
Initially most accordion class mutants were thought to be in the glycinergic pathway due 
to the observation that application of glycine receptor agonist strychnine can cause an 
accordion-like phenotype (Downes and Granato 2006). The mutant bandoneon (beo) has 
been found to harbor a defect in the glycine receptor β-subunit (Hirata et al. 2005). 
Despite this example for a CNS defect in accordion class mutants most mutants seem to 
be affected by impaired muscle relaxation (Gleason et al. 2004; Hirata et al. 2004; Olson, 
Sgourdou, and Downes 2010) or a defect at the neuromuscular synapses (Downes and 
Granato 2004; Lefebvre et al. 2004; M. Wang, Wen, and Brehm 2008). Most mapped 
mutants have turned out to have implications for human diseases and have contributed to 
the understanding of the signaling pathways underlying the symptoms (Downes and 
Granato 2004; Gleason et al. 2004; Hirata et al. 2004; Hirata et al. 2005; Lefebvre et al. 
2004; M. Wang, Wen, and Brehm 2008; Olson, Sgourdou, and Downes 2010; McKeown 
et al. 2012). 
1.4 que mutants belong to the accordion class of motility mutants 
 quetschkommode (que) is an autosomal recessive mutation of the accordion class 
generated in a large-scale ENU screen (Granato et al. 1996). The onset of the phenotype 
was initially been described as 24-28 hpf (Granato et al. 1996) but the onset of the 
behavior may depend on the genetic background and could be variable. In our mixed 
toplongfin-tubingen (TLF-TU) background que mutants display normal spontaneous tail 
coiling behavior at 17 hpf and are capable of touch evoked swimming at 21 hpf. After 72 
hpf, the mutant larvae gradually cease to respond with an initial high amplitude body 
bend also lacking the rhythmic tail movements and instead become increasingly 
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paralyzed at 96 hpf. At this time homozygous mutants respond to touch with rostrocaudal 
compression. This characteristic reaction is thought to be caused by simultaneous long 
lasting contra-lateral muscle activation followed by uncoordinated seizure-like behavior 
characterized by uncoordinated arrhythmic body bends. While que mutants demonstrate 
robust accordion behavior their phenotype was not characterized in detail. In 2007 
Geisler and colleagues mapped several of these mutants as a service to the community 
and linked the que mutation to chromosome 22 leaving the locus of the mutation still to 
be determined (Geisler et al. 2007). At the inception of this thesis it was not known 
whether the que mutation affects locomotion through the central nervous system (CNS), 
primarily at the muscle or through other mechanisms and if homologous mutations have 
been found in humans leading to similar impairment of locomotion. 
1.5 Maple syrup urine disease (MSUD) 
 Proper neuronal network function and locomotion depend on the presence of all 
network components, as well as a controlled environment that allows for proper cellular 
metabolism. In Maple Syrup Urine Disease (MSUD) neuronal networks experience a 
severe increase of branched chain amino acids (BCAA) such as leucine isoleucine and 
valine, leading to severe states of metabolic crisis including seizure, coma and death 
(Kevin A. Strauss and Morton 2003; Chuang, Chuang, and Wynn 2006; Chuang, D. T., 
Wynn, R. M. and Shih, V. E. 2008; Zinnanti et al. 2009; Zinnanti and Lazovic 2012). On 
average up to 100,000 children are affected worldwide (Mackenzie and Woolf 1959) but 
due to founder effects the rate can be as high as 1:200 children in Old Order Mennonite 
communities (Morton et al. 2002). The increased levels of BCAAs are thought to be 
compensated by the mother’s metabolism until birth. After birth BCAA levels quickly 
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rise and result in a burnt sugar smell of bodily secretions. A few days after birth, 
abnormalities in behavior such as repetitive movements like fencing and bicycling can 
occur followed by seizures, coma and death if untreated (Kevin A. Strauss and Morton 
2003). The impaired locomotion is not limited to neonatal stages but can also be triggered 
by severe metabolic shocks in adults. 
 The extent of the MSUD phenotype in patients depends on the amount of residual 
enzyme activity which has been used to separate MSUD disease variants. A residual 
enzyme activity of 0-2% with an onset at birth and severe myelination failure, coma and 
death is considered the classic variant (cMSUD) (Ogier de Baulny and Saudubray 2002; 
Chuang, D. T., Wynn, R. M. and Shih, V. E. 2008). Intermittent (iMSUD) and 
Intermediate MSUD are considered an enzyme activity of 5-20% with an onset between 
0.5-5 years or juvenile stage respectively, both leading to neurological and growth 
impairment as well as seizures (Chuang, D. T., Wynn, R. M. and Shih, V. E. 2008; K J 
Skvorak 2009). A subset of mutations in the E2 subunit (discussed in the next chapter) 
has been shown to response to thiamine with increased enzyme activity and can be 
considered a variant with 2-40% enzyme activity and a late, juvenile onset and a 
phenotype similar to iMSUD (Danner et al. 1985; Fernhoff et al. 1985; Fisher et al. 
1991). 
 Treatment consists of a lifelong diet with reduced amounts of BCAAs adjusted to 
stabilize the BCAA levels in the blood to normal levels. Despite the constant adjustment 
unforeseen events such as sickness or injury can cause a metabolic imbalance and shock 
which can lead to neurological damage (Kevin A Strauss et al. 2010). A second option is 
a liver transplantation followed by lifelong immunosuppression. 
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1.6 Metabolism in MSUD 
 One key metabolic pathway for the digestion of protein is the BCAA degradation 
(Figure 1.1). It converts BCAAs like leucine, isoleucine and valine to CoA conjugates 
required for anabolic processes such as neurotransmitter synthesis, energy generation by 
providing substrates for the Krebs cycle as well as to ensure an osmotic equilibrium in 
the brain through the control of free amino acids (Chuang, D. T., Wynn, R. M. and Shih, 
V. E. 2008; Kevin A Strauss et al. 2010; Knerr et al. 2012).  In a first reversible step, the 
BCAAs are converted into their respective keto acids (BCKA) by several 
aminotransferases in the cytoplasm and mitochondria. The second step is an oxidative 
decarboxylation of the α-keto acids by the mitochondrial branched chain α-keto 
dehydrogenase (BCKD) complex. Multiple enzymes form the BCKD complex (Figure 
1.2). The E2 subunit functions as transacylase and forms a cubic core as a homo-24-mer 
(Chuang, D. T., Wynn, R. M. and Shih, V. E. 2008; Zinnanti and Lazovic 2012). It is 
surrounded by 12 E1 heteromers consisting of α2 and β2 subunits. In addition the E2 core 
has six E3 homodimers attached to it which function as dehydrogenases. Its activity is 
regulated by the BCKD kinase and phosphatase through phosphorylation of the E1 
subunit (Danner and Doering 1998). Mutation in any of the 4 genes coding for the BCKD 
complex can lead to MSUD. Mutations in the E1 and E2 subunit lead to classic or 
intermediate MSUD depending on the residual enzyme activity (Chuang, D. T., Wynn, R. 
M. and Shih, V. E. 2008). Mutation in the E3 subunit involves lactic acidosis as well as 
elevated BCAAs since the E3 subunit is shared with the α-ketogluterate and pyruvate 
dehydrogenases (Chuang, Chuang, and Wynn 2006; Chuang, D. T., Wynn, R. M. and 
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Shih, V. E. 2008). The sweet smell noticed on bodily secretions is due to the high 
concentrations of the keto acid form of isoleucine: α-keto-β-methylvalerate (KMV). 
1.7 Model systems for MSUD  
 Historically MSUD has been primarily been studied in bovine and rodent models 
(K J Skvorak 2009). Calves of the bovine models were mostly stillborn or die quickly 
after birth. In addition the high cost, the difficulties of handling the animals as well as 
inconsistencies when compared to human MSUD made the calve model less attractive as 
a model system (Harper et al. 1989). Several mouse models have been created through 
mutations in the Branched Chain Amino Acid Transferase in the mitochondria (BCATm) 
as well as the E2 and E3 subunits. But no reported mutations in BCATm in humans as 
well as a homozygous embryonic lethality not reflecting human pathology reduced the 
usefulness of these models (Klivenyi et al. 2004; Calingasan et al. 2008; K J Skvorak 
2009). To overcome these drawbacks a classic mouse model was generated through 
knockout of the E2 subunit (Homanics et al. 2006). On top of this background, human E2 
was expressed by a liver specific promoter resulting in 5-6% of normal enzyme activity 
(Homanics et al. 2006). This increased the survival rate to 50% after post natal day 25 
(P25). Interestingly, the majority of these mice showed severe ataxia and dystonia 
(Zinnanti et al. 2009). 
1.8 Effects of elevated BCAA levels on the nervous 
 How exactly the elevated BCAA levels lead to the neurodegeneration and 
abnormal behavior and seizures is not yet completely understood. Most likely it is a 
combination of synergistic effects of several inhibiting and damaging cascades with 
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systemic effects throughout the embryo (Kevin A. Strauss and Morton 2003). One aspect 
is a metabolic imbalance of the neuronal environment in the brain. In the brain of calves, 
rodents and human patients showing abnormal levels of BCAAs a reduction of 
neurotransmitters such as GABA , glutamate and aspartate were significantly reduced 
(Dodd et al. 1992; Kevin A. Strauss and Morton 2003; Funchal et al. 2004; Zinnanti et al. 
2009). This is thought to cause extracellular hypertonicity leading to edemas, a reduction 
of larger amino acids in the brain due to competition at the LAT1 mediated at the cerebral 
barrier and active transport of glutamine out of the brain (Kevin A. Strauss and Morton 
2003). 
1.9 Significance 
 Through identification and functional characterization of the que mutant I 
analyzed a gene that is essential for normal locomotion and potentially for development 
and/or early maintenance of neuronal networks. que mutants reveal a novel gene involved 
in network formation or maintenance and might contribute to the understanding of 
neurological diseases due to the history of useful contributions to the understanding of 
such disorders by previously identified behavioral zebrafish mutants. In addition, MSUD 
has a significant impact on the quality of life of patients including their mental 
performances. A vertebrate model capable of screening through small compound libraries 
would be a very useful tool to find new therapeutic strategies. 
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Accordion 
mutants 
 
gene 
 
description 
 
human disorder 
 
accordion 
 
Serca1 
calcium pump 
(muscle) 
 
Brody’s disease 
 
ziehharmonika 
 
AchE 
acetylcholinesterase 
(muscle) 
congenital myasthenic 
syndrome 
 
bandoneon 
 
Glrb2 
Glycine receptor 
(ß subunit) 
 
Hyperekplexia 
 
diwanka 
 
LH3 
 
glycosyltransferase 
connective tissue disorder 
(Salo et al. 2008) 
 
bajan 
 
ChAT 
choline 
acetyltransferase 
 
myasthenic syndrome 
 
DA5 
 
Serca1 
calcium pump 
(muscle) 
 
Brody’s disease 
 
twister 
 
AChR α 
acetylcholine 
receptor (muscle) 
Slow channel congenital 
myasthenic syndrome 
quetschkommode ? 
expander ? 
squeezebox ? 
 
Table 1.1: Accordion Class Mutants 
Mutants of the accordion class obtained from a mutagenesis screen (Granato et al. 1996). 
Shaded in red: muscle or muscle end plate associated mutations; in green: CNS 
associated mutations. 
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Figure 1.1: Branched Chain Amino Acid Metabolism 
The first step of BCAA metabolism consists of a reversible transamination resulting in 
Keto acid derivates. The second step is an oxidative decarboxylation reaction of the α-
keto acids by the mitochondrial branched chain α-keto acid dehydrogenase complex 
(BCKD). In Maple Syrup Urine Disease activity of the BCKD is reduced or absent 
resulting in accumulation of BCAAs and keto acids. 
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Figure 1.2: Model for regulation of Branched Chain Amino Acids in mitochondria 
Multiple enzymes form the BCKD complex. Branched chain amino acid 
aminotransferases (BCATs) both inside and outside of the mitochondria reversibly 
convert branched chain amino acids (BCAAs) into their keto acid form (BCKAs). The E2 
subunit functions as transacylase and forms a cubic core as a homo-24-mer. It is 
surrounded by 12 E1 heteromers consisting of α2 and β2 subunits. In addition the E2 core 
has six E3 homodimers attached to it which function as dehydrogenases. Its activity is 
regulated by regulation of its phosphorylation by the BCKD kinase and phosphatase. 
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CHAPTER 2 
BEHAVIORAL AND ELECTROPHYSIOLOGICAL CHARACTERIZATION OF 
THE QUE MUTANT 
The following section was modified from (Friedrich et al. 2012) 
2.1 Abstract 
 A common symptom of many neurological diseases is impaired locomotor 
behavior. The neuronal networks required for proper locomotion are established during 
early development but despite recent identification of neurons involved in these networks 
it is still largely unknown what factors are required for proper development and function 
of these networks (Warp et al. 2012).  
 Zebrafish are an excellent model system to study these networks due to their rapid 
external development and a series of distinct locomotor behaviors during embryonic 
development. A powerful tool available in that system is a panel of motility mutants that 
can be used to identify novel genes and factors required for neuronal network formation 
and maintenance (Granato et al. 1996). From this panel I obtained the motility mutant 
quetschkommode (que). To assess whether its inability to swim is CNS or muscle derived 
I analyzed its behavior in detail and compared it to known muscle and CNS defect 
mutants but no distinguishable trend emerged. Since structural effects could also account 
for the observed phenotype I visualized critical structural components such as sensory 
neurons, motor neurons and muscle fibers but found no gross anomalies in the que 
mutant. To better distinguish between the possibilities of que mutants harboring a CNS or 
muscle defect, simultaneous contra-lateral peripheral nerve recordings were performed 
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showing a significant increase of contra-lateral overlap of CNS output indicating 
abnormal CNS output in the mutant. 
2.2 Introduction 
 Zebrafish display a series of well defined locomotor behaviors throughout early 
development starting with spontaneous movements at 17 hpf progressing through touch 
evoked tail coiling and resulting in burst swimming after 27 hpf (Saint-Amant and 
Drapeau 1998; Buss and Drapeau 2001). This series of behaviors is thought to reflect a 
dynamic development and remodeling of neuronal networks in the brain and spinal cord. 
Despite advancements in knowledge about these neuronal networks, their components 
and connectivity, their formation and functional requirements during development are 
largely still unknown.   
 The que mutant was generated in a mutagenesis screen in 1996 (Granato et al. 
1996). While wild-type larvae respond to touch with a high amplitude body-bend with the 
tip of the tail touching the head (C-bend) followed by alternating body bends at 4 dpf 
(Eaton et al. 1977; Zottoli and Faber 2000), que mutants are paralyzed and contract 
rostrocaudally. This compression resembles the contraction of the musical instrument 
accordion which led to the name of the accordion class. Besides the initial classification 
its phenotype has not been characterized in detail. From previous studies it was found, 
that the observed rostrocaudal compression observed in accordion class mutants can be 
caused by CNS defects (Hirata et al. 2005) or anomalies in muscle structure or relaxation 
(Downes and Granato 2004; Gleason et al. 2004; Hirata et al. 2004; Lefebvre et al. 2004; 
M. Wang, Wen, and Brehm 2008; Olson, Sgourdou, and Downes 2010). Independent of 
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the mechanism leading to the observed accordion phenotype most mutants have been 
associated with human diseases and have greatly contributed to their understanding. To 
determine whether que mutants harbor a CNS or muscle defect is crucial for its 
usefulness in studying neuronal network formation and maintenance. 
 For this purpose I used a quantitative behavioral analysis approach to analyze the 
que mutant phenotype in detail. I compared the que mutant phenotype as well as 
structural components of the circuitry and the muscle to known muscle and CNS defect 
mutants. Finally, peripheral nerve recordings were used to analyze CNS output. 
2.3 Materials and methods 
2.3.1 Behavioral analysis 
 To characterize swimming behavior at 4 dpf, at the onset of the que mutant 
behavior, light touch stimuli were applied to the head of larvae using a 1 mm insect pin. 
The response was recorded using a high-speed video camera (Fastec Imaging, San Diego, 
CA), recording 500–1000 frames per second, mounted to a 35 mm lens (Nikon, Melville, 
NY). The head-to-tail angle for each frame was measured using automated software 
developed in the Downes laboratory by Kelly Anne McKeown and Sandy Whittlesey 
(McKeown et al. 2012). In brief, pixel density analysis was used to identify three 
landmarks along the larval body: the tip of the nose, the border between the yolk ball and 
yolk extension, and the tip of the tail. These three points form an angle for each frame 
which was plotted over time using Microsoft Excel. 
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2.3.2 Antibody staining 
 Whole mount immunostaining was performed using standard protocols [similar to 
(Downes and Granato 2004)]. The primary antibodies were mouse anti F59 (1:10, Frank 
Stockdale; Stanford University, Stanford, CA) labeling fast muscle fibers, mouse anti 
acetylated tubulin (1:400; Sigma, St. Louis. MO) staining sensory neurons and anti SV2 
(1:100, Kathleen Buckley, Stanford University, Stanford, CA) labeling synaptic vesicles 
of motor neurons. Secondary antibody was Alexa Fluor 594 goat anti Mouse (1:1000 
dilution, A11005, Molecular Probes, Sigma, St. Louis, MO). Images were acquired using 
a confocal microscope (Nikon, Melville, NY). Z-stack picture series were generated and 
overlaid using the EZ Viewer program (Nikon, Melville, NY) and Adobe Photoshop (San 
Jose, CA, USA).  Figure 2.2 B4 was modified from (Downes and Granato 2004). 
2.3.3 Electrophysiology 
 Zebrafish larvae at 4 dpf were anesthetized with 0.02% Tricaine-S (Western 
Chemical) in extracellular recording solution (Legendre and Korn 1994; Drapeau et al. 
1999; Masino and Fetcho 2005) and paralyzed with 0.1% (w/v) α-bungarotoxin (Sigma), 
which significantly reduced or abolished postsynaptic muscle activity based on patch 
recordings from muscle fibers (Masino and Fetcho 2005). The extracellular solution was 
superfused continuously at 22-26°C. Larvae were pinned in a dorsoventral position to a 
Sylgard-lined glass-bottom Petri dish and the skin was removed. Extracellular suction 
electrode recording techniques were used to monitor the activity of peripheral nerves 
during fictive behavior (Masino and Fetcho 2005). Activity occurred spontaneously but 
was also initiated by gently applying a touch stimulus to the head with a tungsten pin 
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controlled and positioned by a manual micromanipulator (MX130, Siskiyou, Grants Pass, 
OR). The tip of the extracellular suction electrode (~15 µm tip diameter) was positioned 
at the dorsoventral midline of a myotomal cleft where the skin had been removed. All 
extracellular recordings were restricted to between body segments 7 and 15. A 
MultiClamp 700B (Molecular Devices, Sunnyvale, CA) amplifier was used to monitor 
extracellular voltage in current-clamp mode at a gain of 1000 (Rf=50 MΩ) with the low- 
and high-frequency cut-off at 100 and 4000 Hz, respectively. Recordings were sampled at 
10 kHz. Extracellular recordings were digitized using a digitizing board (DigiData series 
1440A, Molecular Devices, Sunnyvale, CA) acquired using pClamp 10 software and 
rectified offline. 
2.4 Results and discussion 
2.4.1 que mutants exhibit abnormal rostrocaudal compressions in response to touch 
 A single allele of que (ti274) was identified from a previously performed 
mutagenesis screen (Granato et al. 1996; Zottoli and Faber 2000). The mutation is 
recessive, and homozygous mutants first demonstrate abnormal rostrocaudal 
compressions at around 72 hpf (data not shown). The abnormal behavior becomes more 
robust by 96 hpf. At this time point, high-speed video analysis shows that wild-type 
larvae respond to touch by first performing a large amplitude body bend, defined here as 
greater than 110°, followed by lower-amplitude body undulations to swim away (Figure 
2.1A). By contrast, que mutants do not perform the initial C-bend or lower-amplitude 
body undulations, and instead demonstrate rostrocaudal shortening (Figure 2.1B). Other 
mutants have been shown to demonstrate this accordion behavior due to defects in either 
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CNS function, such as bandoneon (beo, Table 2.1) (Hirata et al. 2005), or muscle 
relaxation, such as accordion (acc, Table 2.1) (Gleason et al. 2004; Hirata et al. 2004; 
Hirata et al. 2005; Olson, Sgourdou, and Downes 2010). I used kinematic analysis to 
analyze the swimming behavior of que mutants and compare it to the CNS defect mutant 
beo and the muscle defect mutant acc to determine whether I could distinguish defects in 
CNS function from defects in muscle relaxation. No clear trend emerged; however, que 
mutants consistently show the most dramatic disruption of swimming behavior compared 
to acc or beo mutants. Although acc and beo mutants demonstrate abnormal swimming 
behavior, C-bends are often observed (Figure 2.1C-E). By contrast, que mutants very 
rarely execute large-amplitude body bends (Figure 2.1F). que mutants continue to 
perform accordion behavior 5-6 days post-fertilization (dpf). They fail to inflate the swim 
bladder, which would enable them to feed, and eventually die around 7 dpf. 
2.4.2 que mutants do not exhibit gross muscle or nerve structure defects  
 It has been shown that the accordion phenotype can result from CNS defects as 
well as muscle defects (Downes and Granato 2004; Hirata et al. 2005) or might result 
from secondary structural defects in sensory and/or motor neurons. To visualize potential 
structural defects in these tissues antibody staining for fast muscle fibers (Figure 2.2B), 
developing sensory neurons (Figure 2.2C) and motor neurons (Figure 2.2D) was 
performed. The results for que were compared to wild-type and beo mutants as well as to 
ziehharmonika (zim) (Downes and Granato 2004), a known muscle mutant with structural 
defects in muscle development. Defects observed in muscle fiber patterning observed in 
the zim mutant (Figure 2.2 B4) were not observed in que mutants (Figure 2.2 B3). No 
severe structural abnormalities were observed in sensory neurons (Figure 2.2C3) or motor 
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neurons (Figure 2.2 D3). Although smaller defects in synapse distribution and 
interneurons cannot be ruled out at this level of analysis, the absence of gross structural 
defects is consistent with the hypothesis that the mutation does not affect behavior 
through altering muscle structure. 
2.4.3 que mutants demonstrate abnormal CNS motor output 
 To better examine whether que mutants harbor a defect in CNS function as 
opposed to a defect in muscle relaxation, we analyzed fictive locomotor output from the 
spinal cord by performing extracellular peripheral nerve recordings on motor neurons of 
paralyzed larvae. This analysis was performed in collaboration with Aaron Lambert and 
Mark Masino at the University of Minnesota. Zebrafish larvae demonstrate bouts of 
motor output in response to touch (Figure 2.3 A,B). These bouts are composed of tightly 
coordinated bursts that alternate rapidly between the left and right sides and orchestrate 
the axial muscle contractions that constitute swimming. In wild-type larvae, we observed 
rapid alternations in locomotor output between the left and right sides with little overlap 
in bursting activity (6.5 +/- 6%, n=5; Figure 2.3C), as described previously (Masino and 
Fetcho 2005). In que mutants, although the coordination of left-right locomotor activity 
was similar to wild-type siblings (compare Figure 2.3C, D), the amount of overlap 
between left-right bursting activity was significantly higher (19.1 +/- 11.3 %, n=7; t = -
2.3, p < 0.05). This increase in activity overlap is consistent with the simultaneous left-
right muscle contractions performed by que mutants. These data do not rule out the 
possibility that que mutants contain a defect in muscle relaxation; however they indicate 
that abnormal motor output from the CNS at least contributes to this mutant’s behavior. 
To further characterize potential differences in locomotor output between wild-type and 
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que mutant siblings, we examined a range of bout and burst properties related to rhythmic 
locomotor activity during fictive swimming (Masino and Fetcho 2005). Though most of 
these properties were not significantly different between wild-type and mutant larvae, que 
mutants generated a significantly greater number of bouts following the touch stimulus 
applied to the head than did wild-type larvae [11.6 +/- 6.2 bouts and 1.9 +/- 0.9 bouts, 
respectively (t = 3.5, p < 0.01, n = 5)]. These results suggest that there are subtle, yet 
significant, changes in the locomotor circuit that underlie swimming in que mutant larvae 
that participate in generating the mutant behavioral phenotype. 
2.4.4 Significance 
 I characterized the behavior of que mutants in detail. I showed that que mutants 
begin to show abnormal behavior around 4 dpf in our mixed genetic background. They 
exhibit a reduction of both C-bend amplitude and alternate body bends afterwards and 
quickly become paralyzed. I visualized structural components of the escape response 
circuitry and found no obvious structural effects consistent with the hypothesis that the 
behavior observed is not based on structural abnormalities obtained during development. 
We analyzed the CNS output and found significant overlap of left-right motor output 
suggesting that the mutation directly or indirectly affects the escape circuitry at or 
upstream of motor neurons. 
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Figure 2.1: que mutants exhibit abnormal swimming behavior at 96 hpf 
(A,B) Selected frames from high-speed video recordings are shown with times indicated 
in milliseconds. (A) A wild-type larva demonstrates a normal C-bend (A4, asterisk) in 
response to a touch stimulus, followed by smaller-amplitude body undulations to clear 
the field (A5-A12). (B) A que mutant demonstrates abnormal rostrocaudal shortening and 
it fails to escape. (C-F) Kinematic traces are shown, with zero degrees indicating a 
straight body and positive and negative angles representing body bends in opposite 
directions. Time is shown in seconds. Ten representative traces are shown for each 
phenotype. (C) Wild-type embryos typically perform a C-bend (defined here as greater 
than 110°; asterisks) followed by smaller-amplitude body undulations. (D) bandoneon 
(beo) mutants, which contain a CNS defect and demonstrate behavior similar to que, 
sometimes perform a C-bend followed by abnormal body bends. (E) accordion (acc) 
mutants, which contain a muscle relaxation defect and also demonstrate behavior similar 
to que, sometimes perform a C-bend but fail to perform smaller-amplitude body bends. 
(F) que mutants rarely perform a C-bend and demonstrate few smaller amplitude body 
undulations. 
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Figure 2.2: que mutants do not exhibit gross nerve or muscle structure defects 
In each panel, lateral views are shown, with dorsal up and rostal to the left.  Embryos of 
que and wild-type embryos at 96 hpf were stained with antibodies against F59 (fast 
muscle myosin), acetylated tubulin (developing sensory neurons) and SV2 (motor 
neurons). The muscle fiber alignment is normal in both mutants (B1-B3). Both, sensory 
(C1-C3) and motor neuron projections (D1-D3) do not differ in location and distribution 
in either mutant compared to wild-type (A1-D1).  Structural defects observed in the 
muscle mutant zim (B4) (Downes and Granato 2004) were neither observed in que nor 
beo mutants. 
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Figure 2.3: The spinal locomotor output is altered in que mutants 
(A,B) Representative single extracellular peripheral nerve recordings from (A) wild-type 
and (B) a que mutant. que mutants produce a greater number of bouts following a gentle 
tap to the head (arrow) than do wild-type. (C,D) Representative paired (left-right) 
extracellular peripheral nerve recordings in which (C) wild-type fish demonstrate tightly 
coordinated bursting activity with little overlap. By contrast, (D) que mutants generate 
greater bursting overlap. Gray bars denote burst activity in the top trace and extend to the 
bottom trace for ease of comparison. 
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bout and burst properties Wild-type que mutants 
No. of bouts 1.9±0.9 8.6±7.3* 
Bout duration (msec) 329.1±60.4 285.2±148.8 
No. of bursts per bout 9.5±1.9 9.7±3.6 
Burst duration (msec) 13.3±2.8 12.4±1.7 
Burst duty cycle (%) 30.9±11.8 39.6±6.8 
Burst frequency (Hz) 31.6±4.6 37.6±9.3 
Mean contra-lateral phase (%) 49.6±1.2 50.4±7.7 
Bursting overlap (%) 6.5±6.0 19.1±11.3** 
 
Table 2.1: Comparison of bout and burst properties related to fictive locomotor 
activity in wild-type and que mutants 
All values presented as mean ± s.d. Significant differences are indicated by *P<0.05 or 
**P<0.01. 
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CHAPTER 3 
MOLECULAR IDENTIFICATION OF THE QUE LOCUS 
 
3.1 Abstract 
 In the previous study the results suggested that the abnormal locomotor phenotype 
observed in que mutants is at least partially due to abnormal CNS output (Chapter 2). 
Therefore the mutated gene in the que larvae promises to be essential for locomotor 
network development and/or function. I mapped the que gene to 0.36cM on chromosome 
22 and found a splice site mutation in the splice donor site of exon 6 of dihydrolipoamide 
branched chain transacylase E2 (dbt). This enzyme is one of the key enzymes in branched 
chain amino acid metabolism and can cause Maple Syrup Urine Disease (MSUD) when 
DBT is mutated in humans. Embryos injected with an anti-dbt morpholino showed 
reduction of dbt protein expression and similar reduction of C-bend and alternating body 
bends as que mutants. Taken together these results suggest dbt is the gene mutated in que 
mutants. 
3.2 Introduction 
 The aim of this study is to characterize the zebrafish mutant que and use it as a 
tool to study neuronal network formation and maintenance. In the previous study (chapter 
2) abnormal CNS output was observed in addition to disrupted locomotor behavior 
consistent with the hypothesis that the observed disrupted ability to swim is at least 
partially based on impaired neuronal networks. Having thus established that abnormal 
CNS output is most like contributing to the abnormal locomotor behavior, I pursued a 
positional cloning approach to determine the mutated gene in que mutants, which is 
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required to better understand the mechanism behind the seizure like behavior of que 
mutants and to identify potential corresponding genetic disorders in humans. 
3.3 Methods 
3.3.1 Chromosomal mapping and sequence analysis 
 Crosses between fish heterozygous for the que allele (carriers) and WIK fish were 
used to generate a three-generation map cross panel. F2 que mutant embryos and wild-
type siblings were collected, sorted based upon the 96 hpf phenotype and stored in 
methanol at –20°C. DNA was extracted from more than 833 mutant larvae, and SSLP 
markers and SNP markers were obtained and generated against genes to refine the 
mapping interval. Exons and intron-exon boundaries of candidate genes were sequenced 
(Genewiz, South Plainfield, NY) from wild-type, que siblings and homozygous mutants. 
3.3.2 Morpholino analysis 
 Wild-type zebrafish embryos were pressure injected at the one- to four-cell stage 
with 12 ng of morpholino designed to block translation of dbt or the standard control 
morpholino (Gene Tools, Phinomath, OR). This amount of morpholino was selected 
based upon dose-response experiments in which higher doses were found to generate 
morphological defects and/or lethality. The sequence of the translation-blocking 
morpholino was 5’-CGCACAGTAATGACCGCCGCCATCT-3’. Underlined residues 
indicate the start codon. The control morpholino sequence was  
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5’-CCTCTTACCTCAGTTACAATTTATA-3’. The embryos were raised at 28.5°C, and 
locomotive behavior was examined across development. Kinematic analysis, as described 
above, was performed at 96 hpf. 
3.4 Results and discussion 
3.4.1 Chromosomal mapping and sequence analysis 
 To determine the molecular identity of the que gene, I used a positional cloning 
strategy. Using a three-generation map cross panel, I screened pools of genomic DNA 
from wild-type siblings and homozygous mutants with a panel of simple-sequence length 
polymorphism (SSLP) markers. que mapped to chromosome 22, which confirmed 
previous low-resolution mapping results (Geisler et al. 2007). I then used DNA extracted 
from single embryos and single nucleotide polymorphism markers to refine the map 
position to a 0.36cM interval between the markers ENSDART109865 and wu:f63d09 
(Figure 3.2A).  Extensive genome database analysis and sequencing of nearby candidate 
genes led me to dihydrolipoamide branched chain transacylase E2 (dbt), a subunit of the 
BCKD complex, which is required for BCAA metabolism. Zebrafish dbt is a predicted 
493 amino acids in length, and it is ~78.2% identical to the human protein (Figure 3.1). 
Mutations in the human DBT gene are known to cause MSUD, which can result in severe 
dystonia and death if not treated. Given that que mutants demonstrate abnormal behavior 
and nervous system function consistent with the severe dystonia observed in humans, I 
sequenced the dbt gene. Sequence analysis of the dbt gene from que homozygotes 
revealed a single nucleotide substitution compared to wild-type in the splice donor site of 
exon 6. The guanine of the intron side of this splice site is changed to an adenine (Figure 
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3.2B). To determine whether this change affects the splicing of intron 6 as would be 
predicted, I performed RT-PCR using one primer in exon 6 and one primer in exon 7 
(Figure 3.2C). I found that RNA extracts from wild-type larvae were spliced according to 
prediction, however RNA extracts from homozygous mutants revealed a larger transcript 
that contained the entire 86 base pairs of intron 6, indicating it was spliced incorrectly 
(data not shown). This intron alters the sequence downstream of Lysine268 and contains 
four stop codons, which would prematurely truncate the dbt protein by 224 amino acids. 
dbt contains an acetyl transferase domain, essential for its function (Chuang, D. T., 
Wynn, R. M. and Shih, V. E. 2008), which would be largely absent from the que mutant 
protein. Interestingly, in humans, a mutation that prematurely truncates the DBT protein 
at the orthologous position (Lysine257) was reported in an individual with the most 
severe or ‘classic’ form of MSUD  (Herring et al. 1992; Chuang, D. T., Wynn, R. M. and 
Shih, V. E. 2008). These data indicate that the que mutation is a loss-of-function allele 
that diminishes or abolishes BCKD complex function. 
3.4.2 Confirmation through phenocopying 
 To further confirm the molecular identity of que, I injected wild-type embryos 
with either a standard control morpholino or a morpholino designed to block translation 
of dbt. Embryos were injected at the 1-4 cell stage and monitored over the course of 
development. Embryos injected with the standard control morpholino exhibited mostly 
normal behavior throughout the course of development (97.2% of surviving larvae, 
n=107; Figure 3.2D). Notably, 37.5% (n=144) of surviving larvae injected with the 
morpholino designed to target dbt demonstrated clear rostrocaudal compressions and 
fewer large amplitude body bends at 96 hpf, similar to que mutants (Figure 3.2E). In 
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addition, I noticed a strong decrease of dbt protein in the mutant (Figure 3.3). It is 
important to note that morpholinos are known to lose effectiveness ~4-5 dpf due to 
turnover, which likely explains why not all embryos injected with the dbt morpholino 
demonstrated the robust accordion behavior exhibited by que mutants (Bill et al. 2009). I 
also attempted to perform rescue experiments in mutant embryos by injecting mRNA 
encoding dbt at the 1-4 cell stage and analyzing motility behavior at 4 dpf. I did not 
observe rescue (data not shown), however mRNA is known to lose effectiveness ~2 dpf 
due to turnover. The que behavioral phenotype is not apparent until 3-4 dpf, which 
indicates that dbt is required at this stage of development and precludes mRNA rescue. 
Regardless, the mapping data, nature of the que mutation, aberrant mRNA splicing 
observed in mutants, the morpholino phenocopy and the reduced levels of dbt protein in 
que mutants all argue that the que gene encodes dbt. 
3.5 Significance 
 I mapped the mutation in que mutants to chromosome 22 and found a mutation in 
dbt, a key enzyme in the branched chain amino acid metabolism. A homologous 
truncation of dbt has been found in human patients suffering from MSUD (Chuang, D. 
T., Wynn, R. M. and Shih, V. E. 2008). This suggests that the que mutant harbors a 
mutation similar to those found in MSUD patients leading to the observed seizure-like 
phenotype. 
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Figure 3.1: Protein sequence alignment of human and zebrafish dbt 
Needleman-Wunsch alignment. Identity: 68%. Similarity: 78%. Gaps: 5%. A plus 
indicates different amino acids with similar properties. 
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Figure 3.2: The que gene encodes dihydrolipoamide branched-chain transacylase E2 
(dbt), a subunit of the BCKD complex 
(A) que maps to a 0.36 cM interval on chromosome 22. Molecular markers are shown at 
the top and the number of recombinants out of the number of meiotic events is shown at 
bottom. dbt was positioned within the zero recombinant interval. (B) Chromatogram 
sequence traces of dbt from wild-type, hetero and homozygous mutant larvae. The 
nucleotide substitution at the exon-intron boundary (G to A) can be observed in hetero- 
and homozygotes. (C) A schematic of the dbt protein is shown with the boundaries 
between exons indicated as vertical lines. Protein domains, including the acetyl 
transferase domain, are also shown. Below, the wild-type splice pattern is illustrated, with 
protein-coding exon 6, the sequence at the splice site, the intervening intron, and protein 
coding exon 7 depicted. The que mutant splicing pattern is also illustrated, including the 
nucleotide substitution, which results in a failure to remove the intron. The intron 
contains four stop codons (asterisks). RT-PCR results using mRNA from wild-type, que 
mutants and –RT controls are also shown using primers targeted towards exon 6 and exon 
7. A larger DNA product, containing intron sequence, can be observed using mRNA 
isolated from que mutants. (D,E) Ten kinematic traces are shown for embryos injected 
with (D) the control morpholino or (E) a dbt translation-blocking morpholino. Embryos 
injected with the control morpholino perform C-bends (asterisk) and normal swimming 
behavior. dbt morphant embryos demonstrate abnormal swimming behavior and few 
large amplitude body bends, similar to que mutants. 
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Figure 3.3: dbt morpholino decreases dbt protein levels  
Western blot analysis confirmed decreased dbt expression in morpholino treated 
embryos. Top: anti-dbt staining. Bottom: α-tubulin as loading control. 
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CHAPTER 4 
FUNCTIONAL CHARACTERIZATION OF THE DIHYDROLIPOAMIDE 
 BRANCH CHAIN TRANSACYLASE E2 GENE 
 
4.1 Abstract 
 To characterize dbt expression in zebrafish I analyzed spatial and temporal 
expression of dbt using RT-PCR and in situ hybridization. dbt is expressed throughout 
early development with maternal deposition of the transcript. Since MSUD patients 
display a strong increase of BCAAs as one of the key symptoms of MSUD I quantified 
free amino acid levels in the que mutant and found significantly increased levels of 
BCAAs as well as a decrease of neurotransmitters such as glutamate, a decrease that 
takes place in neuronal tissue such as the brain and spinal cord. To further validate the 
que mutant as new model of MSUD I performed a pilot drug screen showing that que 
mutant clutches perform significantly better in the presence of phenylbutyrate; a 
therapeutic drug currently in clinical trials. These results suggest that the zebrafish que 
mutant as a new vertebrate model to study MSUD. 
4.2 Introduction 
 Previous studies have shown that the que mutant harbors a mutation in dbt 
(Chapter 3) leading to abnormal CNS output and seizure-like behavior (Chapter 2). It is 
not yet known when and where dbt is expressed during development in zebrafish. 
Mutations in DBT in humans lead to Maple Syrup Urine Disease which is diagnosed by 
elevated branched chain amino acids (Morton et al. 2002). It is unknown whether a 
mutation in the BCAA metabolism in zebrafish causes the same increase of BCAA.   
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 Zebrafish larvae contain a smaller nervous system than do mammalian systems, 
with fewer numbers of cells. que mutants could therefore be a promising system to better 
characterize the CNS injury caused by the toxicity of elevated BCAA levels. Moreover, 
aquatic nature, the small size, external development and the ability to obtain large 
numbers of zebrafish embryos make them a useful model system for small-molecule 
screens (Zon and Peterson 2010). The behavioral phenotype of que mutants is robust and 
easily quantifiable; therefore, que mutants could be developed into a high throughput 
system to screen libraries of compounds to identify small molecules that improve 
swimming behavior. In a pilot drug screen I tested effects of three different categories of 
compounds:  BCAAs and BCKAs for their role in the BCAA pathway as well as known 
and suspected beneficial drugs based on clinical trials and previous results. Compounds 
that improve the behavioral phenotype of que mutants could be candidate therapeutics for 
individuals with MSUD. 
4.3 Methods 
4.3.1 RT-PCR 
 RT-PCR was used to analyze mRNA splicing in mutants as well as examine 
expression during development. Primers designed against dbt gene exon 6 (5’ 
ATCAAACTAAGCGAAGTTGTCGG-3’) and exon 7 (5’-GCGCAACCGGACCAAC-
3’) were used to amplify cDNA from wild-type and homozygous que mutant larvae. The 
primers used to amplify β-actin were 5’-CACACCGTGCCCATCTATGA-3’ and 5’ 
AGGATCTTCATCAGGTAGTCTGTCAG-3’. The RNAs were reverse transcribed 
using the Omniscript Kit (Qiagen, Venlo, Netherlands). The dbt PCR products were 
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sequenced for confirmation (Genewiz, South Plainfield, NY). RT-PCR reactions were 
performed multiple times to decrease the likelihood of amplification artifacts. 
4.3.2 Whole-mount in situ hybridization 
 Antisense digoxigenin probes were generated against dbt using cDNA (Genbank 
ID BC090917) acquired from Open Biosystems (Huntsville, AL). Whole-mount, 
colorimetric in situ hybridization was performed using established protocols (Thisse and 
Thisse 2008) and examined using a compound microscope (Zeiss, Thornwood, NY) 
attached to a digital camera (Zeiss, Thornwood, NY). Cross sections were generated by 
hand sectioning in situ hybridization stained embryos with a razor blade attached to a 
surgical blade holder. To generate sagittal sections, in situ hybridization stained embryos 
were embedded in 1.5% Agar and 5% sucrose. Blocks were kept in 30% sucrose solution 
overnight. The next day blocks were cut into 20µm thick sections using a cryostat (Leica, 
Buffalo Grove, IL). 
4.3.3 Western Blot Analysis 
 Western Blot analysis was performed using 4 or 5 dpf larvae lysates using 100 
larvae per condition. Proteins were resolved using SDS-PAGE and transferred to a 
nitrocellulose membrane, blocked in PBST containing (v/w) 5% dehydrated milk and 
incubated in primary antibody at 4ºC on a rocking platform. Primary antibodies used 
were Anti-DBT (1:1000; Sigma, HPA026485,St Louis, MO) and Anti-α-tubulin (1:50; 
12G10 DSHB, Iowa City, IA). The transferred blot was washed, incubated in anti-rabbit-
HRP (1:90000: Pierce, IL) or anti-mouse-HRP (1:30 000, Pierce, Rockford, IL) and 
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detected with Immun-Star (Bio Rad, Hercules, CA) or a homemade luminol based 
detection protocol. 
4.3.4 Amino Acid Quantification 
 50 larvae at 96 hpf were sorted based upon the locomotor phenotype, for each 
amino acid quantification experiment. The larvae were flash frozen in liquid nitrogen and 
stored at -80°C. The samples were then homogenized and precipitated with 0.1M Lithium 
Citrate, 3.3% 5-sulphosalicylic acid. The samples were sonicated for 10 minutes and then 
centrifuged at 4,600g for 20 minutes. The supernatant was then applied to VivaSpin500 
size exclusion columns (Sartorium, Germany) and centrifuged at 15,000g for 4 hours. 
The flow-through was stored at -80ºC then sent to the University of California Davis 
California Genome and Proteomics Center to resolve free amino acid concentrations.  
4.3.5 Immunohistochemistry 
 The tissue was prepared by embedding 96 hpf larvae as described for in situ 
hybridization. Double immunostaining was performed using standard protocols [similar 
to (Downes and Granato 2004)]. The primary antibodies were Rabbit anti L-Glutamate 
(1:100, ab9440, Abcam, Cambridge, MA) or rabbit anti DBT (1:500. HPA026485, 
Sigma, St. Louis, MO) and Mouse anti Acetylated Tubulin (1:200, T6793, Sigma, St. 
Louis, MO). 
 Secondary antibodies were Alexa Fluor 488 goat anti Rabbit (1:1000, A11034, 
Molecular Probes/Sigma, St. Louis, MO) and Alexa Fluor 594 goat anti Mouse (1:1000, 
A11005, Molecular Probes, Sigma, St. Louis, MO). Slides were mounted using DAPI 
containing Vectashield (Vector Laboratories, Burlingame, CA). Images were acquired 
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using a confocal microscope (Nikon, Melville, NY). The fluorescent intensity for 
acetylated tubulin and L-glutamate antibody staining was quantified using the EZ Viewer 
program (Nikon, Melville, NY) by collecting entire frames (101283mm2) or selecting a 
region of interest above the notochord (3060mm2) for both channels. The numbers used 
for quantification are the Analog to Digital Converter (ADC) values of L-glutamate 
normalized to acetylated tubulin. 
4.3.6 Pharmacological approach  
 This series of experiments was performed together with Sruthi Satishchandran 
and Laura Stapler. To determine an effective drug concentration dechorionated wild-type 
larvae were incubated in a drug concentration series (range: 100nM-100mM, 5x steps, 
1% DMSO, see Table 4.1) at 24 hpf for 3 days. The concentration chosen was the highest 
drug concentration without behavioral or developmental effect in wild-type and less than 
15% mortality. Wild-type and que mutant clutches were incubated in either the effective 
concentration of a given drug or raised in E3 containing 1% DMSO. To examine 
swimming behavior at 96 hpf, a touch stimulus was used by means of a defined probe 
applying a force of not more than 32mN. To perform time-trial assays, single 96 hpf 
zebrafish larvae were placed at the center of a bull’s eye consisting of concentric circles 
in 2mm intervals (Figure 4.7). The 4mm distance proved to be most accurate. The larvae 
were gently touched on the head and the escape response was recorded using the high-
speed video camera recording at 1000 frames/second. The amount of time was measured 
from when the larval head crossed over the boundary of the inner circle and touched the 
outer circle. Individual larvae were tested once, entire clutches were assayed, and each 
condition was performed multiple times by two different observers. The results were 
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compiled into graphs using DeltaGraph (Redrock Software, Salt Lake City, UT). 
Statistical analysis was performed to compare the average swim times between all 
conditions using the student’s t-test.  
4.4 Results and Discussion 
4.4.1 dbt mRNA becomes enriched in the brain and gut organs during development 
 I examined the spatial and temporal expression of dbt in developing zebrafish. 
RT-PCR revealed that dbt mRNA was present at all time points examined from 6 hpf to 
120 hpf (Figure 4.1A). In situ hybridization also confirmed early expression at the two 
cell stage. dbt was detected at the two-cell stage, indicating it is a maternally deposited 
mRNA (Figure 4.1B). The spatial expression of dbt is initially widespread through 24 hpf 
(Figure 4.1C,D); however, its expression pattern over the next few days of development 
becomes enriched in the brain and organs in the gut, such as liver and intestine (Figure 
4.1E-H). These data suggest that dbt plays an important role in BCAA metabolism 
through function in these tissues. The prominent expression within the brain, in 
particular, suggests that dbt is important for CNS function. 
 To determine the distribution of dbt protein during development antibody staining 
was performed on cross sections of the area above the yolk extension. Due to the high 
protein sequence similarity (Figure 4.1) I tested an antibody against human DBT in 
zebrafish (Figure 4.3). In wild-type an increase of dbt protein expression is observed in 
the periphery as well as in the spinal cord (Figure 4.2C). At 96 hpf dbt protein 
localization is enriched in peripheral structures (Figure 4.2D). It can be detected in the 
gut as well as in the developing pronephric ducts (Figure 4.2J white and orange arrow 
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respectively). In the mutant dbt seems to be mostly absent (Figure 4.2E-H).  Intriguingly, 
the expression pattern of dbt, with progressive enrichment in the brain and gut organs 
over the course of development, is reminiscent of another mitochondrial protein that is 
important for CNS function, Opa3 (Pei et al. 2010). 
4.4.2 que mutants harbor elevated levels of BCAAs 
 In mammalian systems, impaired DBT function, as demonstrated by MSUD-
affected individuals, results in elevated levels of BCAAs (Kevin A. Strauss and Morton 
2003; Chuang, Chuang, and Wynn 2006; Chuang, D. T., Wynn, R. M. and Shih, V. E. 
2008). Because dbt is disrupted in que mutants, I investigated their free amino acid 
profiles. Owing to the small size of larval zebrafish, a homogenate of 50 whole animals 
was used for each assay. I compared the free amino acid levels of wild-type and que 
mutant larvae at 96 hpf. Strikingly, que larvae harbor elevated levels of BCAAs (Figure 
4.3A,B). Isoleucine, leucine and valine concentrations were 788%, 1006% and 688% 
(n=3, P<0.01) of those of wild-type, respectively. que mutants also showed a marked 
decrease in free glutamine levels, at 24% of wild-type (n=3, P<0.01). In addition, 
statistically significant decreases were observed in the levels of a wide variety of free 
amino acids, including aspartate (16%), GABA (32%) and serine (28% of wild-type; all 
n=3, P<0.01); and alanine (44%), glutamate (38%), glycine (41%), methionine (49%) and 
threonine (60% of wild-type; all n=3, P<0.05). To rule out the possibility that abnormal 
motor behavior itself alters free amino acid levels, I examined beo mutants, which 
contain a mutation in the glycine receptor β2 subunit and exhibit abnormal behavior 
similar to que mutants (Figure 4.3C) (Hirata et al. 2005). The free amino acid levels in 
beo mutants (n=1) were similar to that of wild-type controls, indicating that accordion 
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behavior alone does not substantially alter free amino acid concentrations. Combined, 
these data provide strong evidence that mutation of the que gene results in an error in 
amino acid metabolism, yielding a prominent accumulation of BCAAs. 
4.4.3 Glutamate levels are reduced in the brain of que mutant larvae 
 Although the neuropathology of MSUD is not well understood, reduced 
concentrations of neurotransmitters, including glutamate, were observed in the 
intermediate MSUD mouse model (Zinnanti et al. 2009). Neurotransmitter depletion was 
found to correlate with abnormal motor behavior and a highly abnormal posture 
consisting of recumbency and stiff, extended limbs. Given that our analysis of the free 
amino acids levels in que mutants showed decreased concentrations of free glutamate and 
these mutants demonstrate abnormal CNS function and motor behavior, I examined the 
distribution of glutamate using an antibody recognizing glutamate and tested it in 
zebrafish. As a control for antibody penetration and overall tissue morphology, I also 
stained acetylated tubulin using an acetylated tubulin antibody. Antibody penetration and 
general morphology of the brain of que mutants seemed similar to wild-type at 96 hpf 
(compare Figure 4.4 A with D). By contrast, glutamate levels were markedly reduced in 
que mutant larvae (n=5 embryos, 12 sections, P<0.01; compare B with E; G). In wild-
type larvae an increase of glutamate is observed during development (Figure 4.5A-D). At 
96 hpf glutamate is found both in the periphery as well as in the spinal cord (Figure 
4.5D). In the mutant dbt seems to be mostly absent (Figure 4.5E-H) which probably 
contributes to the abnormal nervous system function and behavior observed by this stage 
of development.  
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4.4.4 The working model 
 The findings from this study, as well as observations in rodent and human 
systems, suggest a model for how mutation of the zebrafish dbt gene leads to abnormal 
swimming. In mammalian systems, dbt is required for the second step of BCAA 
metabolism, and its impairment leads to elevated levels of BCAAs and α-keto acids in 
plasma and tissue (Chuang, Chuang, and Wynn 2006; Chuang, D. T., Wynn, R. M. and 
Shih, V. E. 2008). Elevated BCAAs in the plasma, in particular leucine, are thought to 
out-compete other amino acids at the blood-brain barrier, which results in 
neurotransmitter deficiencies, growth restrictions, cytotoxic edema, myelin disruption, 
and impaired energy metabolism throughout the CNS (Zinnanti et al. 2009). α-keto acid 
toxicity has also been proposed to directly disrupt CNS function. Intracranial injection of 
α-ketovaleric acid, which is derived from valine, has been shown to elicit seizures in rats, 
whereas administration of other α-keto acids had no behavioral effect (Coitinho et al. 
2001). In individuals with MSUD, reducing the concentrations of BCAAs and α-keto 
acids in the plasma by liver transplantation can protect CNS function and development 
(K A Strauss et al. 2006). 
 I propose that very similar mechanisms regulate BCAA metabolism in zebrafish 
(Figure 4.6). Throughout the first 5 days of zebrafish development, the embryo consumes 
the presumptive equivalent of a high-protein diet in mammals by absorbing BCAA 
containing proteins from the yolk (Link, Shevchenko, and Heisenberg 2006; Tay et al. 
2006). During the earliest stages of development, within the first few hours post-
fertilization, the metabolic needs of the embryo are largely met by maternally derived 
mitochondria and mRNA (Mendelsohn and Gitlin 2008; Zhang et al. 2008; Abrams and 
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Mullins 2009). However, as embryogenesis proceeds, BCAA metabolism increasingly 
relies upon zygotic transcription. In wild-type embryos, BCKD complex function in the 
liver, other gut organs and the brain itself protect the CNS from BCAA toxicity, similar 
to mammalian systems. According to this model, BCKD complex function supports 
appropriate import of amino acids across cerebral barriers, robust metabolic generation of 
neurotransmitters, which are essential to support the coordinated CNS output that 
generates vigorous swimming behavior. In que mutants, our data indicate that mutation of 
dbt disrupts BCKD complex function to cause the toxic accumulation of BCAAs and 
probably α-keto acids. This error would cause abnormal retention due to insufficient 
removal capacities, import of amino acids into the CNS, reduced levels of glutamate and 
other neurotransmitters, abnormal CNS function leading to accordion behavior (Figure 
4.6). It will be interesting to use transgenic approaches to determine whether restoring 
gene function in the liver of que mutants preserves normal CNS function, as shown in 
mammals (K A Strauss et al. 2006; Kristen J Skvorak, Hager, et al. 2009; Kristen J 
Skvorak, Paul, et al. 2009). Driving gene expression in other organs not yet explored in 
mammals can also be investigated, which might indicate new therapeutic options for 
individuals with MSUD. 
4.4.5 Pharmacological evaluation of the working model 
 The mutation in the dbt gene in que mutants affects dbt protein expression (Figure 
3.3), free amino acid and glutamate levels (Figure 4.2) and leads to abnormal CNS output 
(Figure 2.3) and impaired swimming (Figure 2.1). The mechanism behind these results is 
not yet fully understood. It is still unclear whether there is one dominant part of the 
cascade such as the glutamate reduction that is the key factor or if multiple factors, such 
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as the toxicity of the BCAAs, their keto-acids in addition to a lack of neurotransmitter 
and neurodegeneration cause the observed phenotype. que mutants as a vertebrate model 
for MSUD could be a powerful tool to answer these questions with but it is still unknown 
how results obtained using que mutants relate to established models and humans. 
 I therefore performed a pilot drug screen using metabolites known to be 
upregulated in que mutants such as BCAAs and their keto-acids, therapeutics currently 
used to treat MSUD such as thiamine and phenylbutyrate and compensatory compounds 
such as nor-leucine thought to compete with leucine and glutamine as a precursor for 
glutamate which has not yet been proposed as useful drug for MSUD treatment (Table 
4.1). Whole wild-type and que clutches were incubated at 24 hpf until 96 hpf when time 
trial analysis was performed. While almost all larvae in the 4mm test were able to finish 
the task roughly 25% in que mutant clutches failed and either failed to leave the inner 
circle (paralyzed, p) or failed to connect with the 4mm mark (impaired, I) (Figure 4.8A, 
B). At the highest concentration with less than 15% lethality none of the drugs had an 
effect on wild-type swimming speeds (Table 4.1; Figure 4.8 G). When applied to que 
clutches phenylbutyrate (Figure 4.8 C) and α-keto-β-methylvaleric acid (KMV) (Figure 
4.8D) improved the average swimming speed of the swimming fraction of the clutch. 
This effect is considered to be mainly affecting the heterozygote larvae since drug 
application had no effect on wild-types and still roughly 25% don’t complete the task 
which most likely represents the homozygous mutant fraction. To determine whether 
drug application affects the distribution of swimming performance categories in que 
mutant clutches I performed a Χ2-test (Figure 4.8H). While KMV did not alter the 
distribution significantly, α-ketoisocaproic acid (KIC) treated clutches had a higher 
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percentage of paralyzed larvae while application of glutamine and phenylbutyrate slightly 
reduced this fraction. 
4.5 Significance 
 que larvae harbor a mutation in zebrafish dbt, which results in elevated BCAA 
levels, similar to both the mouse models of MSUD and affected humans. In the mouse 
model of intermediate MSUD, elevated levels of BCAAs have been shown to correlate 
with progressive disruption of CNS function and concomitant defects in motor behavior 
that culminate in severe dystonia (Silberman, Dancis, and Feigin 1961; Morton et al. 
2002; Zinnanti et al. 2009). Similarly, severe dystonia has been reported in MSUD-
affected individuals during acute metabolic decompensation (Silberman, Dancis, and 
Feigin 1961; Morton et al. 2002; Zinnanti et al. 2009). que mutants demonstrate a 
progressive defect in motor behavior that culminates in abnormal CNS function and 
accordion behavior. Accordion behavior is probably the expression of severe dystonia in 
developing zebrafish. The Downes Lab and others have previously shown that zebrafish 
mutants that exhibit accordion behavior contain mutations in genes known to control 
movement and muscle tone in mammalian systems (Downes and Granato 2004; Gleason 
et al. 2004; Hirata et al. 2005; M. Wang, Wen, and Brehm 2008; Olson, Sgourdou, and 
Downes 2010).  
 The findings from this study indicate that que mutants are a new animal model of 
MSUD. One aspect of MSUD is the distinct, maple syrup smell of bodily secretions of 
affected individuals. I did not detect any distinct odor of que mutants (data not shown); 
however, this is probably due to the small size and minute amounts of secretions 
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produced by larval zebrafish. Nevertheless, que larvae seem to recapitulate molecular, 
biochemical, cellular and behavioral aspects of MSUD. Because larval zebrafish contain 
a smaller nervous system than do mammalian systems, with fewer numbers of cells, que 
mutants provide a promising system to better characterize the progression of CNS injury 
in response to BCAA toxicity. Moreover, the small size, aquatic nature, development that 
is external to the mother and the ability to obtain large numbers of zebrafish embryos 
make them amenable to small-molecule screens (Zon and Peterson, 2010). The 
behavioral phenotype of que mutants is robust, easily quantifiable and can respond to 
known MSUD therapeutics (Figure 4.8); therefore, que mutants could be developed into a 
high throughput system to screen libraries of compounds to identify small molecules that 
improve swimming behavior. Compounds that improve the behavioral phenotype of que 
mutants could be candidate therapeutics for individuals with MSUD. 
 Other aspects of MSUD can also be investigated using larval zebrafish. Gene 
targeting approaches can be readily employed, such as morpholino injection or TALEN 
technology, to model MSUD caused by disruption of other BCKD complex subunits 
(Cade et al. 2012; Moore et al. 2012). These technologies can also be used to examine the 
in vivo role of BCKD regulatory proteins, such as the BCKD phosphatase or kinase. 
Genetic modifier screens can also be performed using the que mutant to search for genes 
that can compensate for disruptions in BCAA metabolism. Taken together, these 
approaches can provide a promising platform to better understand CNS metabolism and 
develop new therapies to combat MSUD. 
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Figure 4.1:  dbt becomes enriched in the brain and organs in the gut across 
development 
(A) RT-PCR results are shown using mRNA isolated at different time points during 
zebrafish development. dbt was detected at all stages examined. –RT and β-actin controls 
are also shown. (B-H) In situ hybridization shows broad dbt expression at (B) the two-
cell stage, (C) 12 hpf and (D) 24 hpf. The inset of a cross section (the black bracket 
indicates the approximate level of the cross-section) reveals robust dbt expression in 
muscle. dbt expression become enriched in the brain and gut at (E) 48 hpf and (F) 96 hpf. 
(G) Sagittal sections of stained 96 hpf embryos illustrate expression in the brain 
(arrowhead) and gut. The white bracket indicates a portion of the region shown at higher 
magnification in H. Above the left edge of the white bracket, dbt expression in the liver 
can be observed, whereas above the right edge of the white bracket, dbt expression in the 
intestine is revealed. 
 
  
49 
 
 
Figure 4.2: dbt protein expression during development 
Antibody staining on cross sections using an anti-DBT antibody (green) over bright field 
images. (A-D) in wild-type dbt expression increases after 72 hpf and is increased in 
peripheral structures such as fast muscle fibers, the gut (J, white arrow) and pronephric 
ducts (J orange arrow). (E-H) in the que mutant the dbt antibody epitope is mostly absent 
throughout development. (I) Comparison of dbt levels over development based on ROI 
fluorescence intensity of all tissue dorsal of the yolk. n=2 embryos. 
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Figure 4.3: The free amino acid profile of que mutants shows elevated levels of 
BCAAs at 96 hpf 
The amino acids are referred to by their three-letter code, except for GABA. Each 
experiment contained a homogenate of 50 larvae. The error bars indicate standard error. 
(A) The free amino acid profile for wild-type larvae (n=3). (B) The free amino acid 
profile of que mutant larvae reveals a dramatic accumulation of BCAAs: isoleucine, 
leucine and valine. Other amino acid levels were reduced. * Significant difference from 
wild-type at P<0.05; ** significant difference from wild-type at P<0.01 (n=3). (C) The 
free amino acid profile of beo, a zebrafish mutant that demonstrates abnormal behavior 
owing to a CNS defect, indicates that abnormal behavior alone does not markedly alter 
free amino acid levels (n=1). 
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Figure 4.4: que mutants contain a reduced concentration of glutamate in the brain. 
(A-F) Cross-sectional views of the hind-brain of 96 hpf larvae are shown. 
Immunohistochemistry using antibodies against acetylated tubulin, which predominantly 
labels axon tracts, reveals the overall structure of the brain and demonstrates tissue 
penetration of the antibodies. Staining using an antibody against L-glutamate illustrates 
the distribution of this neurotransmitter. (A) Labeling with the anti-acetylated tubulin 
reveals the axon tracts and overall structure of the hind-brain of wild-type larvae. (B) The 
hind-brain of wild-type larvae contains a broad distribution of L-glutamate. (C) The 
merged images show several L-glutamate-positive cells surrounded by anti-acetylated 
tubulin labeling. (D) The overall structure of the hind-brain of que mutants revealed by 
anti-acetylated tubulin appears similar to the hind-brain wild-type larvae. (E) The 
fluorescence intensity of labeling with the L-glutamate antibody is greatly reduced 
compared with wild-type when imaged using the same microscope settings. However, 
increasing the gain of the confocal microscope shows more reduced L-glutamate staining 
(inset). (F) The merged images show little L-glutamate staining compared with acetylated 
tubulin labeling. (G) The graph shows a significant reduction in L-glutamate staining 
intensity in que mutants normalized to acetylated tubulin staining. The fluorescent 
intensity values are the analog-to-digital converter values of the entire frame (n=5 
embryos, 12 sections, **P<0.01). Very similar results were obtained when a region of 
interest was selected to encompass a smaller, designated portion of the brain. 
  
52 
 
 
 
 
 
 
  
53 
 
 
Figure 4.5: Levels of Glutamate during development 
Antibody staining on cross sections using an anti-glutamate antibody (green) over bright 
field images. (A-D) in wild-type glutamate seems to be present in both peripheral areas as 
well as in the spinal cord throughout development. (E-H) in the que mutant glutamate 
levels vary during development and seem to be reduced at 96 hpf (H) Comparison of 
glutamate levels over development based on ROI fluorescence intensity of all tissue 
dorsal of the yolk. n=2 embryos for 24-48 hpf; n=4 embryos for 72 hpf, n=6 for 96 hpf. 
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Figure 4.6: A working model of how mutation of dbt results in abnormal, accordion 
behavior 
Similar to mammalian systems, I propose that wild-type zebrafish regulate metabolism of 
BCAAs via the BCKD complex. Many of these metabolic or molecular steps (black 
arrows) might occur in organs in the gut (such as the liver and intestine) but also the 
CNS. Amino acids (AA), such as glutamine, are transported across the blood-brain 
barrier and used to generate glutamate, GABA and other neurotransmitters (NT). These 
neurotransmitters are required for coordinated nervous system output to orchestrate 
swimming behavior. In que mutants, I propose that impaired BCKD function results in 
the accumulation of BCAA and α-keto acids. This yields reduced retention and 
metabolism, and reduced transport of other amino acids (white arrows) across the blood-
brain barrier, resulting in diminished neurotransmitter synthesis. The abnormal levels of 
neurotransmitters contribute to aberrant nervous system output and abnormal, accordion 
behavior. It is also possible that elevated concentrations of α-keto acids directly disrupt 
neural circuits to cause accordion behavior. 
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Compound 
Exp. Effect 
(+/—) 
Concentration 
(mM) 
leucine — 75 
valine — 10 
isoleucine — 2 
 
KMV (α-keto-β-methylvaleric acid) 
 
— 
 
2 
 
KIC (α-ketoisocaproic acid) 
 
— 
 
5 
 
KIV (α-ketoisovaleric acid) 
 
— 
 
10 
norleucine + 40 
thiamine + 1 
sodium phenylbutyrate + 0.01 
glutamine + 0.4 
 
Table 4.1: Compounds and concentrations used for pharmacological pilot screen 
For a small pilot screen 10 small compounds were chosen consisting of BCAAs, their 
keto-acids, drugs currently used in clinical trials and glutamine suggested to be beneficial 
based on previous results. Their expected effect is noted as well as the highest 
concentration found to result in less than 15% mortality in wild-type. 
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Figure 4.7: Bull’s Eye for kinematic analysis 
Larvae were placed in the middle of the inner circle. A touch stimulus was applied and 
the time measured between leaving the inner cycle and reaching the 4mm mark. 
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Figure 4.8: Pharmacological evaluation of the model 
Comparison of swimming speeds of whole clutches after drug application. Percentage of 
the clutch swimming 4mm per time bin. I:percentage of fish leaving the inner circle. P: 
paralyzed percentage. Embryo numbers, average swimming speed and time given in the 
upper right corner. (C-F) que mutant clutch swimming speeds after drug application. (G) 
Comparison of swimming speeds; KMV and phenylbutyrate treatment increases 
swimming speeds in que mutant clutches. (H) Χ2-analysis; while KIC slightly increases 
the percentage of larvae unable to perform the task, glutamine and phenylbutyrate 
improve the swimming performance of that fraction. 
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CHAPTER 5 
SUMMARY AND FUTURE DIRECTIONS 
 
 We used the zebrafish motility mutant que for the purpose of finding a new gene 
and molecular event required for locomotion. Since it was unclear at the beginning of this 
work whether que mutants harbor a CNS or muscle related defect I characterized its 
behavior and showed, that it is similar to both, known muscle and CNS mutants. Wild-
type larvae respond to touch with a C-bend and alternating body bends at 96 hpf while 
que mutants fail to perform C-bends and display rostrocaudal shortening instead followed 
by uncoordinated body bends. To rule out obvious structural defects I used 
immunohistochemistry and stained fast muscle fibers, sensory and motor neurons but 
observed no severe structural defects in morphology or distribution. To answer the 
question whether que mutants have a CNS defect we used peripheral nerve recordings to 
show that the amount of left-right overlap of bursts is significantly increased in the 
mutant in addition to an increase of swimming bouts. These findings are consistent with 
the hypothesis that the phenotype in que mutants is at least partly caused by abnormal 
CNS output.  
 I used meiotic mapping to locate the mutation in que mutants to a 0.36cM interval 
on chromosome 22. The most promising candidate gene of the interval, dihydrolipoamide 
branched chain transacylase E2 (dbt) was sequenced and I found a mutation in the splice 
donor site of Exon 6 leading to integration of the adjacent intron. This intron sequence 
codes for four stop codons leading to a truncation of the protein by 224 amino acids 
including the active site which was confirmed by RT-PCR. Injection of a translation 
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blocking morpholino copied both the phenotype as well as the reduction of dbt protein 
observed in the mutant. These results strongly suggest that dbt is the mutated gene in que 
mutants.  
 I found that dbt is expressed throughout early development and gets enriched in 
the hind brain as well as the gut region and the liver at 96hpf. Since dbt is a key 
component of the BCAA metabolism we quantified free amino acid levels. While BCAA 
levels where severely elevated we also noticed a strong reduction of neurotransmitters 
such as GABA and glutamate. To localize this reduction within the embryo I used anti 
glutamate immunohistochemistry and observed a strong decrease of glutamate in the 
hindbrain and spinal cord. To further test the pathway leading from the mutation in dbt to 
the observed phenotype we used a pharmacological approach. In this pilot screen we 
limited ourselves to the key metabolites in the BCAA pathway such as the BCAAs and 
their keto acids as well as therapeutic drugs currently used in clinical trials such as 
thiamine, norleucine and phenylbutyrate. In addition previous results showed a reduction 
of glutamine, a precursor for glutamate, suggesting glutamine as a potential beneficial 
drug to test. While the results for both BCAAs as well as their keto acids varied, 
application of glutamine and phenylbutyrate improved aspects of the swimming 
performance of mutants. 
5.1 que mutants as a zebrafish model for MSUD 
 Many aspects and qualities of the que mutant make it a good model for MSUD. 
First, the model system has some extremely useful qualities such as large clutch size, 
transparency, external development and an aquatic habitat which can facilitate drug 
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application. Second, the que mutant displays a very robust, distinct phenotype at 96 hpf 
which facilitates sorting and scoring. The phenotype is also quantifiable and can be 
detected by automated motion tracking software. Unfortunately it is this robust phenotype 
that can also be challenging since it lacks a dynamic range; experiments relying on 
improving the phenotype have to overcome the effects of early BCAA accumulation 
which can be difficult. It is unknown whether developmental defects occur in zebrafish 
due to BCAA accumulation and it would be difficult for late genetic or pharmacological 
rescue approaches to compensate for such defects even if at later stages the gene would 
have been rendered functional. The fact that MSUD patient’s mental capacity declines 
after every metabolic crisis suggests that damage can occur and is in fact accumulative , 
even if metabolic balance is restored after crisis (Kevin A. Strauss and Morton 2003; 
Fernstrom 2005).  
5.2 Future directions  
 This thesis provides a new model form MSUD and evaluated its application for 
therapeutic screens. While we have identified a reduction of neurotransmitter in this 
zebrafish model the details of what role this reduction of neurotransmitter plays in 
MSUD has yet to be addressed. The cascade of events leading from the accumulation of 
BCAAs to the observed phenotype is still unknown.  
5.2.1 The role of Glutamate and neurotransmitter reduction 
 The observed neurotransmitter reduction could be the cause for the observed 
phenotype. One way to test this hypothesis would be to replenish or at least elevate 
glutamate levels in the que mutant. We attempted this by making use of the 
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technotrousers (tnt) mutant which has a mutation in the glial glutamate transporter 
slc1a2b (McKeown et al. 2012). If a lack of glutamate is indeed causing the phenotype 
then blocking the glial glutamate transporter in que mutants should increase synaptic 
glutamate and might restore the swimming capability of que mutants. In this first attempt 
que mutants injected with a morpholino knocking down slc1a2b failed to show increased 
performance in time trial assays (control injected que clutch: 20% phenotype, n=40; 
slc1a2 MO injected que clutch: 57% phenotype, n=30). I also tried the reverse 
experiment and injected tnt mutants with the dbt morpholino and also saw no significant 
effect on their performance (control injected tnt mutants: 92% phenotype, n=23; slc1a2b 
MO injected tnt mutants: 84% phenotype, n=30). There are several possibilities to 
explain this outcome. First, it could have been, that we didn’t elevate or decrease 
glutamate levels enough to overcome the loss of glutamate in que mutants or decrease the 
glutamate levels effectively in tnt mutants. Second, there are other key effects, 
unaddressed by focusing on glutamate alone. We found that GABA levels are also 
reduced. And patients are known to have a reduction of dopamine, norepinephrine, 
aspartate among other neurotransmitters and precursors (Kevin A. Strauss and Morton 
2003; Zinnanti et al. 2009; Zinnanti and Lazovic 2012).  
5.2.2 Screening for therapeutic compounds 
 The pilot screen confirmed beneficial effects of phenylbutyrate and glutamine. 
These results are encouraging and suggest that further evaluation can be performed to 
develop que mutants as a large-scale drug screening tool. A pitfall for expanding screens 
is the difficulty of having a quantifiable output that is still in a dynamic range of the 
spectrum of measurements. The results of our pilot screen indicate that, while the readout 
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is very robust, the range of results is not dynamic; the changes in swimming speeds or 
distribution are not yet applicable for a large scale screen.  
Two strategies could be considered to overcome this problem. Ideally the behavior as 
output should remain since it is the behavior that is most striking and a key element in 
human MSUD patients as well. To establish a dynamic range the morpholino could be 
used and titrated down to the smallest concentration that still produces the phenotype. At 
this threshold concentration treatment conditions with beneficial effects have the highest 
chance to also influence the behavior. Injection experiments are normally rather difficult 
to incorporate into large scale screens but attempts have been made to automate the 
process (W. Wang et al. 2007) which could facilitate large-scale experiments. Second, 
another readout method could be used. Focusing on the glutamate reduction the use of 
genetic glutamate reporters could be evaluated (Hires, Zhu, and Tsien 2008) to 
circumvent the need for IHC. 
 Based on the literature it is unlikely that one compound alone will have the 
strongest effect. A screen should therefore incorporate conditions of two or more 
compounds to uncover potential synergistic effects (Kevin A. Strauss and Morton 2003; 
Chuang, D. T., Wynn, R. M. and Shih, V. E. 2008) 
5.2.3 Tissue specific rescue 
 One way of treating MSUD patients at the moment is a liver transplantation. 
Unfortunately the supply of donor organs is limited and standby times can be 
considerably long. Therefore it would be beneficial if other organ suitable for 
transplantation would also have the same or similar effects which is supported by our 
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expression data as well as the fact that in rodents Dbt is expressed in most tissues 
(Doering et al. 1998). To pursue the hypothesis that dbt expression in other organs such 
as kidney, stomach and muscle tissue, general rescue need to be demonstrated as well as 
tissue specific expression. We attempted the first step towards this aim, general rescue, 
through several approaches. I injected dbt transcript into mutant clutches at the 1-4 cell 
stage and quantified the swimming performance at 96 hpf. This failed to improve 
swimming performance. A likely possibility is that the turnover rate of the RNA reduces 
the effects of RNA injection at 96 hpf. We tried to overcome this problem by injecting a 
DNA construct with SV40 driving dbt. It too failed to improve swimming performance 
most likely due to the diluting factor and the choice of the promoter which sometimes 
induces only minimal expression in zebrafish. A construct with CMV driving dbt flanked 
by TOL2 sites for genome integration when coinjected with transposase was generated 
but failed to improve the behavioral phenotype. We tested if injected mutants would have 
increased dbt protein using western blot analysis and found that dbt levels were still 
reduced and comparable to those of uninjected mutants. Sequencing of the CMV 
promoter revealed a sequence alteration which could potentially have reduced expression 
of the construct. The same construct with a β-actin promoter is currently being tested.  
 After having found a robust rescue strategy the promoter could be swapped with a 
tissue specific promoter driving dbt only in one tissue. This approach would not only 
allow spatial control but coupled with conditional gene control such as tet-on system 
(Knopf et al. 2010) could provide temporal control to generate juvenile or adult mutants. 
Such mutants could be used to investigate the mechanisms of acute metabolic crises at 
adult stages, simulating metabolic crises as encountered by many MSUD patients. 
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5.2.4 The pathway from BCAAs to the phenotype 
 In this thesis we showed that the mutation in dbt causes elevated BCAA levels. 
We also observed reduced levels of neurotransmitters and an abnormal CNS output. It is 
unlikely that the model shown in Figure 4.6 represents all aspects both in the linear 
sequence as well as in the multitude of potential parallel pathways influencing the CNS 
and the behavior.  
 We observed expression of dbt in the hindbrain. While the CPG circuitry is 
situated in the spinal cord and by itself sufficient to perform escape responses, the CPG 
could be modulated by abnormal firing patterns in the hindbrain of que mutants. To 
distinguish whether or not edemas or other neuronal abnormalities in the hindbrain 
influence CPG function, the head region could be lesioned off and the touch response 
analyzed at 96 hpf. While an outcome with no change would not rule out a pre-lesioned 
influence of the hindbrain, a change in the response could indicate an influence of the 
hindbrain on the CPG in mutants.  
 Zebrafish also offers the possibility of targeting other components of this 
pathway. Morpholino knockdown and TALEN technology allow to reduce expression or 
terminate expression of other components of the BCKD complex. An interesting first 
target is the E3 subunit since it is involved in both pyruvate dehydrogenase and α-
ketogluterate dehydrogenase complexes in addition to the BCKD complex. 
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APPENDIX 
A MACONDO CRUDE OIL FROM THE DEEPWATER HORIZON OIL SPILL 
DISRUPTS SPECIFIC DEVELOPMENTAL PROCESSES DURING ZEBRAFISH 
EMBRYOGENESIS 
This addition was modified from a joint publication based on a collaboration with 
Michael Barresi and colleagues (de Soysa et al. 2012). 
 
  The Deepwater Horizon disaster was the largest marine oil spill in history, and 
total vertical exposure of oil to the water column suggests it could impact an enormous 
diversity of ecosystems. The most vulnerable organisms are those encountering these 
pollutants during their early life stages. Water-soluble components of crude oil and 
specific polycyclic aromatic hydrocarbons have been shown to cause defects in 
cardiovascular and craniofacial development in a variety of teleost species, but the 
developmental origins of these defects have yet to be determined. We asked whether 
water accumulated fractions (WAF) of the Deepwater Horizon oil could impact specific 
embryonic developmental processes. While not a native species to the Gulf waters, the 
developmental biology of zebrafish has been well characterized and makes it a powerful 
model system to reveal the cellular and molecular mechanisms behind Macondo crude 
toxicity. Here we show significant response reduction and abnormal escape responses in 
developing zebrafish in response to WAF exposure. 
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A.1 Methods 
A. 1. 1 Behavioral analysis 
 In an effort to perform a more conservative assessment of locomotor behavior, 
analysis was carried out using a 50% WAF solution. Embryos exposed to either 50% or 
100% WAF had similar locomotor responses (data not shown). To characterize larval 
swimming behavior at 48 hpf, a light touch stimulus was applied to the head of larvae. 
The minimum stimulus required to elicit a response was determined using pressure 
specific Von Frey filaments. The touch-response was recorded using a high-speed camera 
(Fastec Imaging, San Diego, CA, USA) at 1,000 frames per second (fps). A 35 mm lens 
(Nikon, Melville, NY, USA) was used for magnification. To illustrate the responses, 
single frames taken at 20 ms intervals were overlaid in Adobe Photoshop (San Jose, CA, 
USA). For kinematic analysis, the head-to-tail angles were calculated for each frame 
using automated software developed by the Downes Lab (Biology Department, 
University of Massachusetts, Amherst, MA, USA) (Downes and Granato 2006). In brief, 
pixel density was used to identify three landmarks along the larval body: the tip of the 
nose, the border between the yolk extension, and the tip of the tail. These three points 
form an angle, which was plotted over time using Microsoft Excel (Microsoft 
Corporation, Redmond, WA, USA). To calculate body bend frequency, a full body bend 
was defined as two intervals of more than 50 degrees of opposite directions. To 
determine the duration of a swimming episode, we measured the beginning of a 
swimming episode until the final time the body was straightened to within 20 degrees of 
being straight (defined as 0 degrees). 
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A.1.2 Locomotor behavior 
 During our many WAF treatments it was clearly evident embryos displayed 
irregular swimming behaviors. The locomotor escape response to stimuli is an important 
survival behavior that develops later in embryogenesis. Interestingly, previous studies 
examining the effect of PAHs on zebrafish swimming behavior did not reveal any 
significant phenotypes (Incardona, Collier, and Scholz 2004). Therefore, we 
systematically tested whether exposure to Macondo crude oil WAF impacted swimming 
patterns and escape responses. To do this, we recorded the swimming behavior of 
individual 48 hpf larvae with a high-speed video camera (1,000 frames/second) following 
the administration of a specific touch stimulus (Burgess and Granato 2007). WAF-treated 
embryos demonstrated abnormal swimming behavior and a failure to escape based on 
multiple criteria. WAF-treated embryos showed reduced sensitivity to touch stimuli, as 
demonstrated by 70% response rate for WAF-treated embryos as compared to a 99% 
response rate for untreated control embryos (n = 100 trials from 10 embryos each). When 
a response was produced in WAF-treated embryos they showed a significantly reduced 
frequency of body bends (Control, 39.10Hz; WAF, 18.82Hz; n = 10 each; t-test, P <0.01) 
and swam for less time than untreated control embryos (Control, 875.8ms; WAF, 282ms; 
n = 10 each; t-test, P = 0.01) (Figure A.1). The presence of locomotor behavior 
phenotypes suggests that there could either be a problem with neural transmission or a 
developmental problem resulting from an anatomical deformation in the nervous or 
musculature systems.  
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Figure A.1: Macondo crude oil exposure impaired escape behavior by 48 hpf 
(A) Individual frames from high-speed video recordings are shown for control larvae. 
The images are overlaid in 20 ms intervals and the duration of the response captured 
within the field is indicated. (B) Kinematics traces are shown for 10 escape responses 
each for control larvae. 0º indicates a strait body and positive and negative angles 
represent body bends in opposite directions. The time is indicated in seconds. (C) Image 
overlays for a WAF-treated larva escape response illustrate the failure to clear the field 
that was frequently observed. (D) Kinematic traces for WAF-treated larvae reveal 
reduced, abnormal body bend frequencies. (E) Quantification of body bend frequencies. 
(F) Quantification of the duration of escape responses reveals that WAF-treated larvae 
respond for shorter periods of time. Asterisks in E and F indicate statistically significant 
differences (n = 10, P <0.01). 
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